HER2-targeted agents are highly effective in improving survival in HER2-positive patients.
Therefore, trastuzumab (+/- pertuzumab), both of which target HER2, are part of every regimen endorsed by NCCN for HER2-positive disease.
These are often combined with standard chemotherapy, composed of anthracyclines (such as doxorubicin) and/or taxanes (such as docetaxel and paclitaxel).
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Available at http://www.nccn.org.
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in her2 positive breast cancer. N Engl J Med. 2011;365:1273-1283.